MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2022 International Congress

    Predictors of the change in burden and strain among caregivers of Parkinson’s disease patients

    C. Cores Bartolomé, D. Santos García, T. Fonticoba, M. Feal Painceiras, E. Suarez Castro, C. Martinez Miro, S. Jesus Maestre, M. Aguilar, P. Pastor, L. Planellas, M. Cosgaya, J. Garcia Caldentey, N. Caballol, I. Legarda, J. Hernandez Vara, I. Cabo, L. Lopez Manzanares, I. Gonzalez Aramburu, MA. Avila Rivera, V. Gomez Mayordomo, V. Nogueira, V. Puente, J. Garcia-Soto, C. Borrue, B. Solano Vila, M. Alvarez Sauco, L. Vela, S. Escalante, E. Cubo, F. Carrillo Padilla, JC. Martinez Castrillo, P. Sanchez Alonso, MG. Alonso Losada, MI. Morales Casado, I. Gaston, J. Kulisevsky, M. Blazquez Estrada, M. Seijo, J. Ruiz Martinez, C. Valero, M. Kurtis, O. de Fabregues, J. Gonzalez Ardura, R. Alonso Redondo, C. Ordas, LM. Lopez Diaz, D. Mcafee, P. Martinez Martin, P. Mir (A CORUÑA, Spain)

    Objective: The aim of the present study was to analyze the change in burden and strain after a 2-year follow-up in a cohort of caregivers…
  • 2022 International Congress

    Safety and Efficacy of unilaterally Focused Ultrasound Subthalamotomy in Early Parkinson´s Disease: The EARLY FOCUS I Study

    E. Natera-Villlaba, R. Martínez-Fernández, R. Rodríguez-Rojas, M. Del Alamo, J. Pineda-Pardo, I. Obeso, F. Hernández-Fernández, C. Gasca-Salas, M. Matarazzo, J. Obeso (Móstoles, Madrid, Spain)

    Objective: To assess the safety and efficacy of unilateral FUS subthalamotomy in early PD patients. Background: FUS subthalamotomy is feasible and therapeutically effective in Parkinson´s…
  • 2022 International Congress

    Globus pallidus as a neurosurgical target in the management of levodopa-induced dyskinesias

    A. Simonyan, V. Tyurnikov, V. Poleshuk, A. Simonyan, A. Gushcha (Moscow, Russian Federation)

    Objective: Parkinson's disease (PD) is a neurodegenerative disorder characterized by the development of motor symptoms, as well as some non-motor changes. Symptomatic treatment of PD…
  • 2022 International Congress

    Caregiver burden and quality of life in late stage Parkinson’s disease

    K. Rosqvist, A. Schrag, P. Odin (Lund, Sweden)

    Objective: To describe and assess factors associated with informal caregiver quality of life (QoL) in late stage Parkinson’s disease (PD). Background: In the late stage…
  • 2022 International Congress

    The effects of converting to Dysport from other botulinum toxin type A formulations for treating cervical dystonia patients

    O. Samotus, M. Jog (London, Canada)

    Objective: To investigate whether Dysport increases waning time compared to other botulinum toxin type A (BoNT-A) formulations for cervical dystonia (CD) therapy. Background: BoNT-A injections…
  • 2022 International Congress

    Dysphagia and its relationship to medication intake in Parkinson’s disease

    B. Labeit, E. Berkovich, I. Claus, M. Roderigo, AL. Schwake, D. Izgelov, D. Mimrod, S. Ahring, S. Oeleberg, P. Muhle, V. Zentsch, F. Wenninger, S. Suntrup-Krueger, R. Dziewas, T. Warnecke (Muenster, Germany)

    Objective: This study attempted to obtain a comprehensive picture of medication intake dysphagia in Parkinson’s disease (PD). Specific investigations included 1) An objective, graduated and…
  • 2022 International Congress

    DystoniaBoTXNet: A Deep Learning Platform for Predictive Outcome of Botulinum Toxin Treatment in Isolated Dystonia

    D. Yao, L. O'Flynn, K. Simonyan (Boston, USA)

    Objective: To develop and validate an objective measure of the botulinum toxin treatment outcome in isolated dystonia. Background: Dystonia is characterized by abnormal, often painful,…
  • 2022 International Congress

    Duration of continuous “Good On” intervals and number of motor fluctuations after treatment with IPX203 vs immediate-release carbidopa-levodopa in Parkinson’s disease patients with motor fluctuations.

    R. Hauser, H. Fernandez, J. Aldred, C. Singer, H. Shill, S. Factor, H. Visser, R. D'Souza (Tampa, USA)

    Objective: To compare the duration of continuous “On” without troublesome dyskinesia (“Good On”) intervals and number of motor fluctuations per day in Parkinson’s disease (PD)…
  • 2022 International Congress

    Characterization of nociplastic pains in Parkinson’s disease (PD) with the PD pain classification system (PD-PCS)

    V. Mylius, S. Lloret, N. Fisch, R. Gonzenbach, G. Kägi, J. Möller, F. Brugger, D. de Andrade (Valens, Switzerland)

    Objective: To describe the new category of nociplastic pain (NP). We defined Parkinson's disease (PD)-related pains and allocated them to a mechanistic category by using the…
  • 2022 International Congress

    The Parkinson’s Incidence Cohorts Collaboration (PICC): an international collaboration of incident PD cohorts

    A. Macleod, J. Maple-Grødem, M. Camacho, R. Lawson, D. Bäckström, A. Yarnall, C. Williams-Gray, G. Alves, O. Tysnes, L. Forsgren, C. Counsell (Aberdeen, United Kingdom)

    Objective: To (i) identify all incidence cohorts of Parkinson’s disease (PD) with long-term follow up and (ii) pool data from these cohorts to study PD…
  • « Previous Page
  • 1
  • …
  • 66
  • 67
  • 68
  • 69
  • 70
  • …
  • 153
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • To be or not to bupropion: a drug-induced parkinsonism?
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Life expectancy with and without Parkinson’s disease in the general population
  • An atypical and interesting feature of Parkinson´s disease
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley